DreamCIS Inc

223250 · KQ · Healthcare / Medical Care Facilities

3,815.00KRW-20.00 (-0.52%)

Price History

Full chart

Market Stats

Previous Close3,835.00

Open3,880.00

Day Range3,730.00 – 3,895.00

52-Week Range2,360.00 – 8,640.00

Volume74.57K

Market Cap90.16B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.59

50-Day Avg3,283.50

200-Day Avg4,726.48

About

DreamCIS, Inc. operates as a clinical research organization in South Korea, Europe, China, Asia Pacific, the United States, and Canada. It offers clinical development services; standalone services, including biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd.

Company Details

SectorHealthcare
IndustryMedical Care Facilities
CEOMr. JeongHee Yoo
Employees390
HeadquartersJeokseon-dong, Jeokseon Hyundai Building, Seoul, South Korea, 110-756, Korea
Websitehttps://www.dreamcis.com

Leadership

Mr. JeongHee YooCEO & Executive Director · b. 1970
Mr. Taesik YangExecutive VP & CFO · b. 1969
Ms. GyeongSoon KimCOO, VP and Head of Clinical Operations & Solution Group and Executive Director · b. 1970
Mr. Hyunsung JeonSenior VP and Head of HR & GA Department · b. 1977
Mr. Yu Jin PaekHead of Business Development Department & Executive VP · b. 1975
Ms. Jung-A KimSenior VP & Head of LPS Department · b. 1977
Ms. JiSuk ChoSenior VP & Head of STAT Department · b. 1979
Ms. SooYeon JeongExecutive VP and Head of PV & MW Department · b. 1962
Mr. SeongSik KangVP and Head of Clinical Strategy & Development Group · b. 1972

Financials

Income Statement

Currency: KRW	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	15.96B	19.20B	22.11B	23.49B	26.15B	38.87B	47.84B	58.65B	66.63B
Growth (%)	-	+20.32%	+15.15%	+6.24%	+11.34%	+48.64%	+23.08%	+22.59%	+13.60%
Cost of Revenue	13.62B	12.31B	13.71B	13.87B	17.46B	25.01B	34.91B	40.79B	47.26B
Gross Profit	2.34B	6.89B	8.40B	9.62B	8.69B	13.87B	12.94B	17.86B	19.38B
Gross Margin	14.66%	35.91%	37.99%	40.94%	33.23%	35.67%	27.04%	30.45%	29.08%
Operating Expense	3.39B	3.32B	4.06B	4.82B	5.07B	8.13B	11.35B	12.80B	14.14B
Operating Income	-1.05B	3.57B	4.34B	4.79B	3.62B	5.73B	1.59B	5.06B	5.24B
Operating Margin	-6.59%	18.61%	19.61%	20.41%	13.85%	14.75%	3.32%	8.62%	7.86%
EBITDA	-	-	-	-	-	7.12B	6.75B	8.85B	14.03B
EBITDA Margin	-	-	-	-	-	18.31%	14.10%	15.09%	21.06%
Net Income	-1.12B	3.42B	4.15B	4.85B	3.23B	4.41B	3.74B	5.28B	7.13B
Net Income Margin	-7.02%	17.80%	18.77%	20.66%	12.35%	11.33%	7.81%	9.00%	10.70%
R&D	-	-	-	316.11M	276.73M	439.97M	733.27M	919.91M	720.15M
R&D as % of Total Revenue	-	-	-	1.35%	1.06%	1.13%	1.53%	1.57%	1.08%
Interest Expense	0	0	0	36.76M	88.41M	144.42M	191.03M	199.30M	303.71M
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.16%	0.34%	0.37%	0.40%	0.34%	0.46%

Balance Sheet

Currency: KRW	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	13.54B	17.58B	25.02B	48.59B	56.71B	77.97B	88.63B	118.54B	161.84B
Total Liabilities	10.72B	11.07B	14.27B	12.13B	18.73B	29.01B	31.70B	50.58B	76.04B
Total Equity	2.82B	6.51B	10.75B	36.46B	37.98B	48.96B	54.91B	67.96B	76.42B
Cash	3.16B	6.06B	5.83B	4.17B	3.49B	8.95B	5.80B	22.66B	22.31B
Total Debt	-	-	398.95M	338.47M	-	-	-	-	-

Cash Flow

Currency: KRW	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	1.65B	4.85B	4.28B	3.42B	5.88B	9.08B	7.33B	-85.19M	14.07B
Investing Cash Flow	72.69M	-949.35M	-4.06B	-24.78B	-4.08B	-5.50B	-9.64B	3.61B	-
Financing Cash Flow	-301.22M	-1.00B	-453.54M	19.70B	-2.47B	2.01B	-798.68M	13.24B	-
Capital Expenditure	1.07M	60.26M	57.96M	275.49M	1.12B	627.86M	1.69B	1.49B	668.59M
Free Cash Flow	-	-	-	3.09B	4.76B	8.46B	5.65B	-1.58B	13.40B
FCF to OCF	-	-	-	90.34%	80.98%	93.09%	76.99%	1850.92%	95.25%

Earnings

Report Date	Aug 14, 2020	Nov 13, 2020	Mar 12, 2021	May 17, 2021	Aug 13, 2021	Nov 15, 2021	Feb 18, 2022	May 16, 2022	Aug 16, 2022	Nov 14, 2022	Feb 15, 2023	May 12, 2023	Aug 11, 2023	Nov 14, 2023	Mar 15, 2024	May 14, 2024	Aug 14, 2024	Nov 12, 2024	Mar 13, 2025	May 14, 2025	Aug 12, 2025	Nov 12, 2025	May 13, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	283.32	322.07	206.00	97.00	-24.00	158.00	339.29	38.00	211.09	381.96	136.65	77.86	116.00	15.95	94.53	17.00	32.39	51.78	119.66	35.00	62.37	562.00	-4.73	-176.73
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	-	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	-

Key Statistics & Ratios

Market Cap90.16B

Enterprise Value61.02B

Trailing P/E0.00

Forward P/E0.00

Price / Sales1.23

Price / Book1.08

Revenue (TTM)73.28B

Gross Profit (TTM)19.47B

EBITDA8.23B

Profit Margin0.45%

Operating Margin11.33%

Return on Equity0.78%

Return on Assets2.29%

Shares Outstanding24.60M

Shares Float7.42M

Beta0.59

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Oct 10, 20234:1